RT Journal Article
SR Electronic
T1 SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in serum and saliva of COVID-19-seropositive individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20155853
DO 10.1101/2020.07.16.20155853
A1 Martínez-Fleta, Pedro
A1 Alfranca, Arantzazu
A1 González-Álvaro, Isidoro
A1 Casasnovas, Jose M
A1 Fernández-Soto, Daniel
A1 Esteso, Gloria
A1 Cáceres-Martell, Yaiza
A1 Gardeta, Sofía
A1 Prat, Salomé
A1 Mateu-Albero, Tamara
A1 Gabrie, Ligia
A1 López-Granados, Eduardo
A1 Sánchez-Madrid, Francisco
A1 Reyburn, Hugh T.
A1 Rodríguez Frade, José M.
A1 Valés-Gómez, Mar
YR 2020
UL http://medrxiv.org/content/early/2020/07/18/2020.07.16.20155853.abstract
AB Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses. Conceivably, exposure of antigens released from infected cells could stimulate antibody responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other non-structural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher antibody titres in these assays associated with more severe disease and no cross-reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests and its detection in saliva could be the basis for a rapid, non-invasive test for COVID-19 seropositivity.Competing Interest StatementJMRF, JMC, HTR and MVG are inventors on the European patent Assay for the detection of the Cys-like protease (Mpro) of SARSCoV-2 [EP20382495.8]. IGA had personal fees from Lilly and Sanofi, personal fees and non-financial support from BMS, personal fees and non-financial support from Abbvie, research support, personal fees and non-financial support from Roche Laboratories, non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The rest of the authors declare no potential conflict of interestClinical TrialN/AFunding StatementThis work was supported by the Spanish National Research Council (CSIC, project number 202020E079) and grants from Madrid Regional Government IMMUNOTHERCAN [S2017/BMD-3733-2 (MVG)]; the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF), SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; RETICS Program of ISCIII [RD16/0012/0006; RIER (JMRF); RD16/0011/0012, PI18/0371 (IGA), PI19/00549 (AA)]. The study was also funded by La Caixa Banking Foundation (HR17-00016 to FSM) and Fondo Supera COVID (CRUE-Banco de Santander) to FSMAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:La Princesa Health Research Institute (IIS-IP) Research Ethics Committee (register # 4070); Hospital La Paz Committee (HULP: PI-4101)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on request. No large data set is included in this work